NovaBay® Prescribed drugs, Inc. (NYSE American: NBY), a pharmaceutical organization building and commercializing substantial-top quality, scientifically formulated eyecare and skincare solutions, announces the start of a new marketing campaign concentrating on the massive and developing selection of girls who dress in eyelash extensions. This marketing campaign represents the to start with phase in a bigger progress initiative to introduce the Avenova brand name to an totally new group of magnificence-dependent people.
“Years back, we set up Avenova spray as the premier antimicrobial lid and lash spray amongst optometrists and ophthalmologists. For the to start with time, we are integrating our experience in both the pharmaceutical and splendor industries to deal with an fully new client demographic for Avenova, supplying us the option to increase the manufacturer into a totally new industry phase,” stated Justin Hall, NovaBay CEO.
Quite a few women of all ages are turning to eyelash extensions to boost their overall look when doing away with the will need for mascara. The global lash extension marketplace is projected to improve 7.6% each year to $2.4 billion in revenue by 2031 with the typical shopper obtaining lash extension providers as soon as each four to 6 months and shelling out up to $200 for every assistance. Though common for their aesthetic, lash extensions can draw in oil, dust, dust and particles that may perhaps shorten their lifetime span, result in irritation and boost the probability of eye bacterial infections.
Avenova offers an suitable and differentiated option to these bothersome problems for lash extensions people. Distinctive from water-dependent cleansers and serums on the current market, Avenova is clinically demonstrated to kill an infection-leading to microbes and removes the irritants on lids and lashes. Avenova will not injury the adhesive that retains the extensions in place and can really lengthen the lifetime of these highly-priced and time-consuming attractiveness enhancers.
“This is a breakthrough in the lash extension room that also has the likely to be a sizeable breakthrough for Avenova development as properly!” mentioned Kim Shartsis, newly appointed VP of Commercial for NovaBay. “Avenova features a feasible remedy to a pretty genuine unmet need for customers of lash extensions with the included profit of extending lash life. And for Avenova, this introduces the manufacturer to an totally new, developing cohort of engaged and inspired customers. It’s unusual to see a win-win possibility like this.”
About NovaBay Prescription drugs, Inc:
NovaBay Pharmaceuticals, Inc. is a pharmaceutical firm that develops and sells scientifically developed and clinically proven client products for the eyecare and skincare markets. Avenova® is the most recommended antimicrobial lid and lash spray and DERMAdoctor is a quality skincare manufacturer offering much more than 30 dermatologist-created skincare items offered by means of traditional domestic vendors, digital magnificence channels and intercontinental distributors.
NovaBay Prescription drugs Forward-On the lookout Statements
Besides for historic details herein, issues set forth in this press launch might be ahead searching inside the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which include statements about the commercial progress and long term economic performance of NovaBay Pharmaceuticals, Inc. This release is made up of forward-seeking statements that are based upon management’s current anticipations, assumptions, estimates, projections and beliefs. These statements consist of, but are not restricted to, statements with regards to the prospective impact of these on the net retailers on the Company’s anticipated foreseeable future money success. These statements require recognised and unfamiliar threats, uncertainties and other components that may trigger real effects or achievements to be materially diverse and adverse from all those expressed in or implied by the ahead-seeking statements. Other challenges relating to NovaBay’s enterprise, including hazards that could cause success to differ materially from those people projected in the forward-looking statements in this push release, are in-depth in NovaBay’s most current Kind 10-Q/K filings and Registration Assertion on Type S-1 filing with the Securities and Trade Commission, primarily under the heading “Risk Factors.” The forward-looking statements in this release converse only as of this day, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking assertion other than as needed by regulation.
Socialize and Remain Educated on NovaBay’s Progress
Like us on Fb
Adhere to us on Twitter
Hook up with NovaBay on LinkedIn
Pay a visit to NovaBay’s Internet site
Avenova Acquiring Details
For NovaBay Avenova purchasing information and facts:
Be sure to connect with 800-890-0329 or e mail [email protected]
DERMAdoctor Purchasing Facts
For DERMAdoctor getting information:
Be sure to contact 877-337-6237 or electronic mail [email protected]